The Cooper Companies, Inc. (NASDAQ:COO) Given Average Rating of “Moderate Buy” by Analysts

The Cooper Companies, Inc. (NASDAQ:COO) has received an average rating of “Moderate Buy” from the thirteen research firms that are presently covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $115.00.

COO has been the subject of a number of recent analyst reports. Needham & Company LLC restated a “hold” rating on shares of Cooper Companies in a research note on Thursday, August 29th. Piper Sandler increased their price target on shares of Cooper Companies from $115.00 to $120.00 and gave the company an “overweight” rating in a research report on Thursday, August 29th. Wells Fargo & Company lifted their price objective on shares of Cooper Companies from $110.00 to $115.00 and gave the stock an “overweight” rating in a research report on Thursday, August 29th. Morgan Stanley lifted their price target on shares of Cooper Companies from $95.00 to $104.00 and gave the stock an “equal weight” rating in a report on Tuesday, September 10th. Finally, Stifel Nicolaus reissued a “buy” rating and set a $115.00 price objective (up from $110.00) on shares of Cooper Companies in a report on Thursday, August 29th.

Cooper Companies Trading Down 1.0 %

NASDAQ:COO opened at $105.92 on Tuesday. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.99 and a quick ratio of 1.18. Cooper Companies has a one year low of $75.93 and a one year high of $112.38. The company has a market cap of $21.09 billion, a PE ratio of 62.31, a PEG ratio of 2.63 and a beta of 0.98. The firm has a 50-day moving average of $101.43 and a 200-day moving average of $96.03.

Cooper Companies (NASDAQ:COO) last announced its quarterly earnings results on Wednesday, August 28th. The medical device company reported $0.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.91 by $0.05. Cooper Companies had a return on equity of 9.08% and a net margin of 9.45%. The business had revenue of $1 billion during the quarter, compared to the consensus estimate of $997.30 million. During the same quarter in the prior year, the company posted $0.84 earnings per share. Cooper Companies’s revenue was up 7.8% compared to the same quarter last year. As a group, equities research analysts expect that Cooper Companies will post 3.65 EPS for the current fiscal year.

Insider Activity

In other news, CAO Agostino Ricupati sold 1,601 shares of the company’s stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $108.03, for a total value of $172,956.03. Following the completion of the sale, the chief accounting officer now owns 4,818 shares of the company’s stock, valued at approximately $520,488.54. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, CAO Agostino Ricupati sold 1,601 shares of the stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $108.03, for a total transaction of $172,956.03. Following the completion of the sale, the chief accounting officer now directly owns 4,818 shares in the company, valued at $520,488.54. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Brian G. Andrews sold 24,788 shares of the firm’s stock in a transaction that occurred on Thursday, September 5th. The stock was sold at an average price of $105.90, for a total value of $2,625,049.20. Following the transaction, the chief financial officer now owns 6,614 shares in the company, valued at approximately $700,422.60. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 256,373 shares of company stock worth $27,637,427. 2.00% of the stock is currently owned by insiders.

Institutional Trading of Cooper Companies

Several large investors have recently modified their holdings of the business. Vanguard Group Inc. increased its position in Cooper Companies by 303.0% during the 1st quarter. Vanguard Group Inc. now owns 23,099,975 shares of the medical device company’s stock valued at $2,343,723,000 after purchasing an additional 17,367,502 shares during the period. Kayne Anderson Rudnick Investment Management LLC lifted its holdings in Cooper Companies by 3.0% in the second quarter. Kayne Anderson Rudnick Investment Management LLC now owns 7,820,590 shares of the medical device company’s stock worth $682,738,000 after buying an additional 231,155 shares during the period. Capital World Investors boosted its position in Cooper Companies by 301.7% during the 1st quarter. Capital World Investors now owns 5,654,023 shares of the medical device company’s stock valued at $573,657,000 after acquiring an additional 4,246,519 shares in the last quarter. Janus Henderson Group PLC grew its holdings in shares of Cooper Companies by 279.8% during the 1st quarter. Janus Henderson Group PLC now owns 3,437,064 shares of the medical device company’s stock worth $348,723,000 after acquiring an additional 2,532,186 shares during the period. Finally, Impax Asset Management Group plc raised its position in shares of Cooper Companies by 31.0% in the 2nd quarter. Impax Asset Management Group plc now owns 2,359,798 shares of the medical device company’s stock worth $205,511,000 after acquiring an additional 558,886 shares in the last quarter. 24.39% of the stock is owned by institutional investors.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.